UBS Group Analysts Give Bayer (FRA:BAYN) a €110.00 Price Target

Share on StockTwits

Bayer (FRA:BAYN) received a €110.00 ($123.60) target price from equities researchers at UBS Group in a report released on Tuesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target would suggest a potential upside of 70.54% from the company’s current price.

BAYN has been the topic of several other research reports. Deutsche Bank set a €87.00 ($97.75) price target on shares of Bayer and gave the stock a “buy” rating in a research note on Friday. HSBC set a €85.00 ($95.51) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, June 25th. Warburg Research set a €81.00 ($91.01) price objective on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, July 2nd. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a report on Tuesday, July 7th. Finally, Kepler Capital Markets set a €73.00 ($82.02) price objective on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, June 25th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of €84.41 ($94.84).

Shares of BAYN opened at €64.50 ($72.47) on Tuesday. The company’s fifty day moving average is €65.18 and its 200-day moving average is €65.01. Bayer has a 12 month low of €91.58 ($102.90) and a 12 month high of €123.82 ($139.12).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Why do analysts give a neutral rating?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ralph Lauren Corp  Position Boosted by Nissay Asset Management Corp Japan ADV
Ralph Lauren Corp Position Boosted by Nissay Asset Management Corp Japan ADV
Gilead Sciences  Given New $85.00 Price Target at Piper Sandler
Gilead Sciences Given New $85.00 Price Target at Piper Sandler
Nisa Investment Advisors LLC Decreases Stock Holdings in CenterPoint Energy, Inc.
Nisa Investment Advisors LLC Decreases Stock Holdings in CenterPoint Energy, Inc.
Gildan Activewear Inc  Short Interest Update
Gildan Activewear Inc Short Interest Update
Crescent Point Energy Corp  Short Interest Update
Crescent Point Energy Corp Short Interest Update
Nisa Investment Advisors LLC Raises Stock Holdings in Lexington Realty Trust
Nisa Investment Advisors LLC Raises Stock Holdings in Lexington Realty Trust


© 2006-2020 Ticker Report